Interleukin-12: biological properties and clinical application

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Interleukin-12 (IL-12) is a multifunctional cytokine regulating cell-mediated immunity and bridging innate and adaptive immune responses.
• IL-12 induces T helper 1 differentiation, promoting IFN-gamma production, natural killer, and T cell activity, thereby enhancing cellular immunity.
• IL-12 also mediates antiangiogenic programs through IFN-gamma-inducible genes and lymphocyte-endothelial cell interactions.

Purpose of the Study:

• To explore the immunomodulating and antiangiogenic functions of IL-12 as a rationale for its use in cancer therapy.
• To review the efficacy of IL-12 in preclinical studies and clinical trials for anticancer applications.
• To suggest further evaluation of IL-12 and its family members (IL-23, IL-27) as potential therapeutic agents in cancer patients.

Main Methods:

• Review of preclinical studies demonstrating antitumor and antimetastatic activity of IL-12.
• Analysis of clinical trial data where IL-12 was used as a single agent or vaccine adjuvant.
• Examination of the mechanisms underlying IL-12's immunomodulatory and antiangiogenic effects.

Main Results:

• Preclinical studies consistently show significant antitumor and antimetastatic activity of IL-12.
• Clinical trials using IL-12 as a single agent or adjuvant have generally demonstrated limited efficacy.
• The immunomodulating and antiangiogenic properties of IL-12 are well-documented.

Conclusions:

• IL-12 exhibits potent immunomodulatory and antiangiogenic properties with a strong preclinical basis for anticancer therapy.
• Despite promising preclinical data, clinical efficacy of IL-12 as a monotherapy or adjuvant has been limited.
• Further investigation into the therapeutic application of IL-12 and related cytokines like IL-23 and IL-27 is warranted for improved cancer treatment strategies.